Immune cocktail after transplant shows promise but study halted early
Disease control
Terminated
This study looked at whether giving two immune-boosting drugs (nivolumab and ipilimumab) after a stem cell transplant could help prevent cancer from coming back in people with high-risk multiple myeloma or lymphoma. The trial enrolled 46 adults aged 18 to 80. The main goal was to…
Phase: PHASE1, PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Apr 29, 2026 05:16 UTC